These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 1356011)
1. Novel antitumor peptide hormones and their effect on signal transduction. Kéri G; Balogh A; Horváth A; Mezö I; Vadász Z; Bökönyi G; Bajor T; Vántus T; Teplán I; Horváth J J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):105-10. PubMed ID: 1356011 [TBL] [Abstract][Full Text] [Related]
2. Peptides and antitumor activity. Development and investigation of some peptides with antitumor activity. Teplán I Acta Biol Hung; 2000; 51(1):1-29. PubMed ID: 10866357 [TBL] [Abstract][Full Text] [Related]
3. Gonadotropin-releasing hormone analogues inhibit cell proliferation and activate signal transduction pathways in MDA-MB-231 human breast cancer cell line. Kéri G; Balogh A; Szöke B; Teplán I; Csuka O Tumour Biol; 1991; 12(2):61-7. PubMed ID: 1902971 [TBL] [Abstract][Full Text] [Related]
4. Novel somatostatin analogs with tyrosine kinase inhibitory and antitumor activity. Kéri G; Mezö I; Horváth A; Vadász Z; Balogh A; Idei M; Vántus T; Teplán I; Mák M; Horváth J Biochem Biophys Res Commun; 1993 Mar; 191(2):681-7. PubMed ID: 8096383 [TBL] [Abstract][Full Text] [Related]
5. Antitumour activity of folligen, a novel gonadotropin-releasing hormone analogue against DMBA-induced tumours in the rat. Nicholson RI; Kéri G Tumour Biol; 1992; 13(1-2):44-50. PubMed ID: 1534181 [TBL] [Abstract][Full Text] [Related]
6. Differential effects of LHRH and somatostatin analogs on human breast cancer. Brower ST; Schally AV; Redding TW; Hollander VP J Surg Res; 1992 Jan; 52(1):6-14. PubMed ID: 1347798 [TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationship studies of novel somatostatin analogs with antitumor activity. Kéri G; Mezô I; Vadász Z; Horváth A; Idei M; Vántus T; Balogh A; Bökönyi G; Bajor T; Teplán I Pept Res; 1993; 6(5):281-8. PubMed ID: 7903057 [TBL] [Abstract][Full Text] [Related]
8. Effect of gonadotropin-releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor--positive human cancer cell lines. Pályi I; Vincze B; Kálnay A; Turi G; Mezõ I; Teplán I; Seprõdi J; Pató J; Móra M Cancer Detect Prev; 1996; 20(2):146-52. PubMed ID: 8706040 [TBL] [Abstract][Full Text] [Related]
9. The tumor-selective somatostatin analog, TT2-32 induces a biphasic activation of phosphotyrosine phosphatase activity in human colon tumor cell line, SW620. Vántus T; Csermely P; Teplán I; Kéri G Tumour Biol; 1995; 16(4):261-7. PubMed ID: 7604207 [TBL] [Abstract][Full Text] [Related]
10. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro. Florio T; Thellung S; Corsaro A; Bocca L; Arena S; Pattarozzi A; Villa V; Massa A; Diana F; Schettini D; Barbieri F; Ravetti JL; Spaziante R; Giusti M; Schettini G Clin Endocrinol (Oxf); 2003 Jul; 59(1):115-28. PubMed ID: 12807513 [TBL] [Abstract][Full Text] [Related]
11. The antitumor activity of the somatostatin structural derivative (TT-232) on different human tumor xenografts. Tejeda M; Gaal D; Barna K; Csuka O; Kéri G Anticancer Res; 2003; 23(5A):4061-6. PubMed ID: 14666719 [TBL] [Abstract][Full Text] [Related]
12. A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity. Kéri G; Erchegyi J; Horváth A; Mezõ I; Idei M; Vántus T; Balogh A; Vadász Z; Bökönyi G; Seprõdi J; Teplán I; Csuka O; Tejeda M; Gaál D; Szegedi Z; Szende B; Roze C; Kalthoff H; Ullrich A Proc Natl Acad Sci U S A; 1996 Oct; 93(22):12513-8. PubMed ID: 8901613 [TBL] [Abstract][Full Text] [Related]
13. Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumors. Lee MT; Liebow C; Kamer AR; Schally AV Proc Natl Acad Sci U S A; 1991 Mar; 88(5):1656-60. PubMed ID: 1672042 [TBL] [Abstract][Full Text] [Related]
14. Antiproliferative and GH-inhibitory activity of chimeric peptides consisting of GHRP-6 and somatostatin. Dasgupta P; Singh AT; Mukherjee R Biochem Biophys Res Commun; 1999 Jun; 259(2):379-84. PubMed ID: 10362518 [TBL] [Abstract][Full Text] [Related]
15. Effects of new somatostatin analogs on the cell proliferation of colonic crypts and colonic cancers in rats. Zerek-Mełeń G; Pawlikowski M; Winczyk K; Lachowicz-Ochedalska A; Legowska A; Kwaśny H; Przybylski J; Szadowska A Neuropeptides; 1993 Jul; 25(1):57-60. PubMed ID: 8105412 [TBL] [Abstract][Full Text] [Related]
16. New endocrine approaches to breast cancer. Howell A; Dodwell DJ; Anderson H Baillieres Clin Endocrinol Metab; 1990 Mar; 4(1):67-84. PubMed ID: 1975167 [No Abstract] [Full Text] [Related]
17. Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice. Pinski J; Schally AV; Halmos G; Szepeshazi K; Groot K; O'Byrne K; Cai RZ Br J Cancer; 1994 Nov; 70(5):886-92. PubMed ID: 7947094 [TBL] [Abstract][Full Text] [Related]
18. Novel heptapeptide somatostatin analog displays anti-tumor activity independent of effects on growth hormone secretion. Murphy WA; Taylor JE; Moreau JP; Coy DH Pept Res; 1989; 2(1):128-32. PubMed ID: 2577697 [TBL] [Abstract][Full Text] [Related]
19. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer. Schally AV; Redding TW Proc Natl Acad Sci U S A; 1987 Oct; 84(20):7275-9. PubMed ID: 2890164 [TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of somatostatin mediated by the stimulation of tyrosine phosphatase. Liebow C; Lee MT; Schally A Metabolism; 1990 Sep; 39(9 Suppl 2):163-6. PubMed ID: 1976210 [No Abstract] [Full Text] [Related] [Next] [New Search]